(E)-retinoic acid-4,4,18,18,18-d5 | 78996-15-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (E)-retinoic acid-4,4,18,18,18-d5
• 英文别名: 9-cis-Retinoic Acid-d5；(2E,4E,6E,8E)-9-[3,3-dideuterio-6,6-dimethyl-2-(trideuteriomethyl)cyclohexen-1-yl]-3,7-dimethylnona-2,4,6,8-tetraenoic acid
• CAS: 78996-15-3
• 化学式: C₂₀H₂₈O₂
• 分子量: 305.401
• InChiKey: SHGAZHPCJJPHSC-GOWYKSNKSA-N

物化性质

• 溶解度：
  可溶于甲醇：

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2E,4E,6E-2,6-Dimethyl-7-ethoxycarbonyl-2,4,6-heptatrienal 在 氢氧化钾 、 正丁基锂 作用下， 以 乙醇 为溶剂， 反应 19.2h， 生成 (E)-retinoic acid-4,4,18,18,18-d5
  参考文献：
  名称：

  带有环修饰的视黄酸类似物。合成及药理活性。

  摘要：

  视黄酸的类似物已被合成为β-环geranylidene环的5,6双键和4-亚甲基区域的主要修饰，作为治疗和预防上皮癌的潜在药物。这些修饰旨在通过降低有效治疗剂量来降低类维生素A毒性，因为主要的代谢失活途径会被抑制。（E）-3,7-二甲基-9-（exo-2-bicyclo [2.2.1]-庚基）-2,4,6,8-壬酸酯（7），（E）-3,7-乙基二甲基-9-（2,2,6-三甲基双环[4.1.0]庚-1-基）-2,4,6,8-壬酸戊酸酯（18），（E）-1-（4-碳乙氧基苯基）- 2-甲基-4-（2,2,6-三甲基双环[4.1.0]庚-1-基）-1,3-丁二烯（28），（E）-视黄酸-4,4,18,18， 18-d5（39）和乙基（E）-3,7-二甲基-9-（3,3-ethano-2,6,6-三甲基-1-环己烯-1-基）-2,4,6 ，

  DOI：

  10.1021/jm00142a018

文献信息

• Methods and compositions for the treatment of proliferative disorders
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US10265288B2

  公开（公告）日：2019-04-23

  The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors.

  本发明的特点是通过施用维甲酸化合物治疗增殖性疾病的方法，该增殖性疾病的特征是受试者体内Pin1标记物水平升高和/或Pin1 Ser71磷酸化降低。此外，本发明还具有通过施用维甲酸化合物与另一种抗增殖化合物联合治疗增殖性疾病（例如，以Pin1标记物水平升高为特征的增殖性疾病）的方法。最后，本发明还包括发现和验证 Pin1 抑制剂的高通量筛选方法。
• Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US10548864B2

  公开（公告）日：2020-02-04

  The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.

  本发明的特征是能够与Pin1结合的全反式维甲酸（ATRA）相关化合物，以及通过施用ATRA相关化合物治疗以Pin1标记物水平升高、Pin1降解和/或Pin1 Ser71磷酸化降低为特征的增殖性疾病的方法。本发明的另一个特点是通过施用 ATRA 相关化合物与另一种治疗化合物联合治疗增殖性疾病、自身免疫性疾病和成瘾病症（例如，以 Pin1 标记水平升高为特征的疾病、病症和病症）的方法。
• Arsenic trioxide for treatment of PIN1-associated disorders
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US10980835B2

  公开（公告）日：2021-04-20

  The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.

  本发明涉及用三氧化二砷治疗Pin1相关疾病（例如，以Pin1活性升高为特征的疾病），可选择与维甲酸化合物联合使用。Pin1相关疾病可包括与Pin1活性异常水平相关的增殖性疾病（如癌症）、炎症和自身免疫性疾病等。
• DAWSON, M. I.;HOBBS, P. D.
  作者：DAWSON, M. I.、HOBBS, P. D.

  DOI：——

  日期：——
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  申请人：Lu Kun Ping

  公开号：US20140086909A1

  公开（公告）日：2014-03-27

  The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors.